Case Type: Mergers & Acquisitions

NeueHealth, Inc. (NASDAQ: NEUE), relating to the proposed merger with New Enterprise Associates. Under the terms of the agreement, holders of NeueHealth common stock will receive $7.33 per share in cash.

Maiden Holdings, Ltd. (NASDAQ: MHLD), relating to the proposed merger with Kestrel Group LLC. Under the terms of the agreement, each issued and outstanding common share of Maiden will be converted into the right to receive one common share in the combined company.

Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), relating to the proposed merger with Immedica Pharma AB. Under the terms of the agreement, Immedica will acquire outstanding shares of Marinus common stock for a cash purchase price of $0.55 per share.

Vacasa, Inc. (NASDAQ: VCSA), relating to the proposed merger with Casago. Under the terms of the agreement, Casago will acquire all outstanding shares of Vacasa held by public stockholders at a price of $5.02 per share.

Vincerx Pharma, Inc. (NASDAQ: VINC), relating to the proposed merger with Oqory, Inc. Under the terms of the agreement, Oqory equity holders are expected to own approximately 95% of the combined entity, while Vincerx equity holders will hold 5%.

Liberty TripAdvisor Holdings, Inc. (OTC: LTRPA, LTRPB), relating to the proposed merger with Tripadvisor, Inc. Under the terms of the agreement, shares of Liberty TripAdvisor Common Stock will be converted into the right to receive $0.2567 in cash.

VOXX International Corporation (NASDAQ: VOXX), relating to the proposed merger with Gentex Corporation. Under the terms of the agreement, Gentex will acquire all issued and outstanding shares of VOXX common stock not already owned by Gentex for a purchase price of $7.50 per share.

NeuroMetrix, Inc. (NASDAQ: NURO), relating to the proposed merger with electroCore, Inc. Under the terms of the agreement, shareholders of NeuroMetrix will be entitled to receive the equivalent of the balance of NeuroMetrix’s net cash at the closing of the transaction, estimated to be $9 million in the aggregate.

Penns Woods Bancorp, Inc. (NASDAQ: CARA), relating to the proposed merger with Tvardi Therapeutics, Inc. Under the terms of the agreement, Cara Therapeutics stockholders are expected to own approximately 17.0% of the combined company.

Penns Woods Bancorp, Inc. (NASDAQ: PWOD), relating to the proposed merger with Northwest Bancshares, Inc. Under the terms of the agreement, Penns Woods shareholders will be entitled to receive 2.385 shares of Northwest common stock for each share of Penns Woods common stock they own.